scPharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCPH research report →
About the company
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients.
- CEO
- John H. Tucker
- IPO
- 2017
- Employees
- 162
- HQ
- Burlington, MA, US
Price Chart
- Market Cap
- $302.20M
- P/E
- -7.99
- P/S
- 10.87
- P/B
- -14.29
- EV/EBITDA
- -9.00
- Div Yield
- 0.00%
- Gross Margin
- 69.48%
- Op Margin
- -115.32%
- Net Margin
- -135.88%
- ROE
- 285.64%
- ROIC
- -53.11%
- Revenue
- $36.33M · 167.28%
- Net Income
- $-85,148,000 · -55.35%
- EPS
- $-1.91 · -34.51%
- Op Income
- $-64,776,000
- FCF YoY
- -19.02%
- 52W High
- $6.28
- 52W Low
- $1.94
- 50D MA
- $5.34
- 200D MA
- $3.86
- Beta
- 0.30
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on SCPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 25 | SCHAEFFER LEONARD D | other | 43,104 |
| Oct 7, 25 | SCHAEFFER LEONARD D | sell | 19,750 |
| Oct 7, 25 | SCHAEFFER LEONARD D | sell | 30,000 |
| Oct 7, 25 | SCHAEFFER LEONARD D | sell | 16,300 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 30,000 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 19,750 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 6,124 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 16,300 |
| Oct 7, 25 | Abraham William Tober | sell | 19,750 |
| Oct 7, 25 | Abraham William Tober | sell | 16,300 |
Our SCPH coverage
Recent articles, reports, and earnings notes.
No research on SCPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCPH report →Similar companies
Peers in the same neighborhood.